Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
27.05.2025 15:45:03

EQS-News: MeVis publishes figures for the first half of fiscal year 2024/2025

EQS-News: MeVis Medical Solutions AG / Key word(s): Half Year Report/Half Year Results
MeVis publishes figures for the first half of fiscal year 2024/2025

27.05.2025 / 15:45 CET/CEST
The issuer is solely responsible for the content of this announcement.


Bremen, May 27, 2025 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, today announced its results for the first half of fiscal year 2024/2025, reporting period October 1, 2024 to March 31, 2025.

In the first half of the year, the Company's revenue amounted to € 8,438 thousand (previous year: € 8,774 thousand). Of this amount, 22% (previous year: 27%) was attributable to the sale of licenses, 34% (previous year: 35%) to maintenance revenues, and 44% (previous year: 38%) to other revenues, which include, among other things, services for and charges passed on to affiliated companies and the parent company. Earnings before interest and taxes (EBIT) fell from € 2,092 thousand to € 1,853 thousand, mainly due to lower sales compared with the previous year, higher other operating income and increased personnel expenses, corresponding to an EBIT margin of 22%.

Income from loans as financial assets amounted to € 550 thousand (previous year: € 258 thousand) and is attributable to interest income from the loan granted to Varex Imaging Deutschland AG. This results in earnings before taxes (EBT) of € 2,468 thousand (previous year: € 2,735 thousand).

Income taxes of € 64 thousand (previous year: € 74 thousand) were incurred in the first half of the year. Therefore, taking into account the expense from the profit to be transferred to Varex Imaging Deutschland AG in the amount of € 2,404 thousand (previous year: € 2,661 thousand), net income amounted to € 0 thousand (previous year: € 0 thousand). It should be noted that the expense from the transfer of earnings only arises legally at the end of the fiscal year.

At this point in time, we are sticking to our forecast: stable to slightly growing sales in the range of € 17.0 million to € 17.5 million are expected for the 2024/2025 financial year. In addition to stable sales with the customer Hologic, sales in the lung and liver segments are expected to increase slightly. We expect development services to remain stable. We expect earnings before interest and taxes (EBIT) for the financial year 2024/2025 to be between € 3.5 million and € 4.0 million, assuming a stable exchange rate of 1.12 USD/EUR. The forecast stability or slight increase in sales and the disproportionately low increase in personnel costs are the main drivers of the positive EBIT outlook.

The Executive Board will regularly review its expectations over the course of the 2024/2025 financial year on the basis of current business developments.


Contact:
Kirchhoff, Marcus / CEO


27.05.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: MeVis Medical Solutions AG
Caroline-Herschel-Str. 1
28359 Bremen
Germany
Phone: +49 421 224 95 0
Fax: +49 421 224 95 999
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2146352

 
End of News EQS News Service

2146352  27.05.2025 CET/CEST

Analysen zu MeVis Medical Solutions AG

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

3 neue Aktien 📈 im BX Musterportfolio: Intuit, Deutsche Boerse & Euronext mit François Bloch

Im BX Morningcall werden folgende Aktien analysiert und erklärt – heute mit dem monatlichen Rebalancing:
NEU✅ Talanx
NEU✅ ANEA
NEU✅ Commerzbank

inklusive Rebalancing:
❌ TransDigm
❌ FISERV
❌ Motorola Solutions

👉🏽 https://bxplus.ch/bx-musterportfolio/

3 neue Aktien 📈 im BX Musterportfolio: Talanx, AENA & Commerzbank mit François Bloch

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’874.48 19.65 SS4MTU
Short 13’152.63 13.68 BFTSNU
Short 13’673.80 8.63 U2TBSU
SMI-Kurs: 12’366.17 06.06.2025 17:31:34
Long 11’879.30 19.97 BIESRU
Long 11’607.67 13.99 BVTSDU
Long 11’071.03 8.72 BMYSUU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}